Strongbridge Biopharma plc (NASDAQ:SBBP) headquartered in Trevose, will host a conference call for the investment community to discuss the 3Q20 earnings result on 29th October 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.strongbridgebio.com
Earnings Expectation
Strongbridge Biopharma plc is set to announce third quarter earning results on Thursday 29th October 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, SBBP to report 3Q20 loss of $ 0.13 per share. For the full year, analysts anticipate top line of $ 27.80 million, while looking forward to loss of $ 0.58 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 28.00 million ~ $ 29.00 million
Click Here For More Historical Outlooks Of Strongbridge Biopharma plc
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The companys commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushings syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly.
